| NCT ID | NCT06529614 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tongji Hospital |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-07-20 |
| Primary Completion | 2025-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-07-20 with a primary completion date of 2025-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
We designed a new in-site detection method for MicroRNA in the serum of patients with breast cancer.
Eligibility Criteria
Inclusion Criteria: Healthy without serious diseases \- Exclusion Criteria: * situations that may affect the results
Contact & Investigator
Shabei Xu, Dr.
STUDY DIRECTOR
Tongji Hospital
Frequently Asked Questions
Who can join the NCT06529614 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 75 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06529614 currently recruiting?
Yes, NCT06529614 is actively recruiting participants. Contact the research team at 616732045@qq.com for enrollment information.
Where is the NCT06529614 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT06529614 clinical trial?
NCT06529614 is sponsored by Tongji Hospital. The principal investigator is Shabei Xu, Dr. at Tongji Hospital. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.